The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus

• Yuan Liu ,

  Contributed equally to this work with: Yuan Liu, Josephine Ye

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Josephine Ye ,

  Contributed equally to this work with: Yuan Liu, Josephine Ye

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Luisa Shin Ogawa,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Takayo Inoue,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Qin Huang,

  Affiliation Department of Pharmacology and Laboratory Medicine, VA Boston Healthcare System, West Roxbury, Massachusetts, United States of America

  ⨯
• John Chu,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Richard C. Bates,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Weiwen Ying,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Andrew J. Sonderfan,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Patricia E. Rao,

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯
• Dan Zhou

  * E-mail: DZhou@syntapharma.com

  Affiliation Synta Pharmaceuticals Corp., Lexington, Massachusetts, United States of America

  ⨯